Mallinckrodt agreed to acquire Questcor for approximately $5.6B in cash and stock ($30 cash plus 0.897 Mallinckrodt shares per Questcor share), centering the deal on Acthar Gel, which generated $761M in 2013 net sales. The transaction closed August 14, 2014 at a final value of approximately $5.8B and later drew federal scrutiny over Acthar pricing.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Stalled
Assessment window: 10yr post-close.
Key facts
AnnouncedApr 07, 2014
ClosedAug 14, 2014
Deal value$5.6B
Deal typeAcquisition/Merger
Therapeutic areaMultiple sclerosis exacerbations, infantile spasms, nephrotic syndrome, lupus, RA
IndicationsMultiple sclerosis exacerbations, infantile spasms, nephrotic syndrome, lupus, RA